Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Lenomorelin structure

Lenomorelin

Growth Hormone
Approved Research
80%
Low-Moderate Risk
2/5

Dosing Protocol

Typical Dose 100 mcg
Range 50 - 250 mcg

Pharmacokinetics

Half-Life 11 min
Onset 5 min
Peak 15 min
Duration 1.0 hrs
Bioavailability 95%
Primary Route Intravenous

Administration

Routes Intravenous, Subcutaneous
Injection Sites IV Infusion
Needle Gauge 25-27G
Syringe Type Standard
Timing Fasted, research protocol

Reconstitution

Diluent Sterile Saline
Volume 1 mL
Stability 1 days refrigerated

Special Instructions

Endogenous hormone - primarily research use. Acylated form required for receptor activity. Very short half-life requires IV infusion for sustained effects. Desacyl form is inactive at GHSR.